STOK Stoke Therapeutics, Inc.

NASDAQ
$24.80

Stoke Therapeutics, Inc. (STOK) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.88 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.8% since its last earnings release on August 3, 2026.

Stoke Therapeutics Missed Consensus Estimates
Monday, August 3, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.88)
Rev est $8.28M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $30.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Stoke Therapeutics, Inc.

Stoke Therapeutics is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.